Citation

Umıt EG, Baysal M, Bas V, Asker I, Kırkızlar O, Demır AM. J. Oncol. Pharm. Pract. 2019; ePub(ePub): 1078155219835303.

Affiliation

Faculty of Medicine, Department of Hematology, Trakya University, Edirne, Turkey.

Copyright

(Copyright © 2019, SAGE Publishing)

DOI

10.1177/1078155219835303

PMID

30890065

Abstract

PURPOSE: Multiple myeloma is a chronic, uncurable hematological cancer with the involvement of multiple organ systems. As a disease affecting older patients, the treatment of multiple myeloma should be based on individual patient characteristics. Polypharmacy is an increasing problem in the care of older patients and in patients with multiple myeloma, polypharmacy is almost inevitable. We aimed to evaluate the applicability of polypharmacy definitions and the relation of polypharmacy with disease outcomes in patients with multiple myeloma.

METHODS: Eighty patients older than 65 years and diagnosed with multiple myeloma were retrospectively enrolled. Patient files, prescriptions, evaluations for polypharmacy were determined according to Beers and START/STOPP criteria. Outcomes were recorded from files in terms of fractures, autonomous neuropathy, and renal functions.

RESULTS: Polypharmacy with ≥4 drugs was observed in 65 patients while polypharmacy with ≥5 drugs was observed in 51 patients. Autonomous neuropathy, polypharmacy with more than four or five medications, and use of multiple medications in the same category were related with poor ECOG performance status in women, while prolonged use of benzodiazepines and central nervous system (CNS) affecting drugs and inappropriate polypharmacy were more frequent in men with poor ECOG performance status. The majority of patients aged 75-84 years were observed to use inappropriate polypharmacy. Autonomous neuropathy and fall risk were observed to be significantly related with inappropriate polypharmacy.

CONCLUSIONS: Drugs affecting balance and perception should be reconsidered in patients with multiple myeloma.

Language: en

Keywords

Myeloma; fall risk; neuropathy; polypharmacy